BullFrog AI
$0.73
+0.0024 (0.33%)
One Giant Leap For Mankind
Join the BullFrog AI Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow BullFrog AI as new developments unfold.
Company Overview
BullFrog AI is a technology company delivering best-in-class AI solutions—including its bfLEAP® platform, originally developed at Johns Hopkins Applied Physics Lab—to help biopharma partners make smarter, faster decisions across the drug development spectrum. Operating with a focused, highly efficient structure, each new partnership offers significant upside potential. The Company is actively engaged in discussions with several prospective pharma partners while expanding commercial reach through its global Sygnature Discovery collaboration, expected to generate meaningful near-term revenue with far larger opportunities ahead. Through its exclusive access to the world’s largest repository of human brain data from the Lieber Institute, BullFrog has already identified multiple novel targets in neuropsychiatric disorders, an area defined by long-duration treatment use and attractive revenue-sharing potential. In oncology, BullFrog’s work with Eleison Pharmaceuticals recently led to an abstract acceptance at the 2026 ASCO GI Symposium, a major validation of the Company’s technology that could become a powerful commercial catalyst when data is released around January 2026.
Value Proposition
BullFrog AI aims to transform drug discovery and development by delivering precision insights through artificial intelligence. Its bfLEAP® platform—originally developed at the Johns Hopkins Applied Physics Lab—analyzes complex biomedical data to uncover patterns and relationships that traditional tools routinely miss. Paired with bfPREP™, BullFrog’s AI-powered data standardization engine, the Company provides partners with a seamless, end-to-end solution for converting messy, multimodal datasets into decision-ready intelligence that can accelerate R&D, reduce risk, and improve the odds of clinical success.
The Company’s commercial model is designed for scale and efficiency. A collaboration with Sygnature Discovery, a leading CRO, brings BullFrog Data Networks™ to biopharma clients globally and is expected to generate $15–$30 million revenue through 2028, establishing a strong foundation with minimal incremental expense. Because BullFrog operates with a highly efficient cost structure, each new partnership delivers meaningful financial leverage, especially as enterprise clients expand from initial modules into multi-solution engagements.
A core strategic advantage is BullFrog’s exclusive access to the world’s largest human brain data repository through the Lieber Institute, enabling discovery of novel targets in neuropsychiatric disorders, an area defined by chronic treatment regimens and substantial long-term revenue-sharing potential. This unique dataset has already revealed multiple new targets, positioning BullFrog as a sought-after collaborator among large pharmaceutical companies seeking innovations in mental health.
The Company is also actively engaged in discussions with several top-tier pharma organizations across neuroscience and oncology, with potential relationships structured to include upfront payments, milestones, and long-term revenue sharing. BullFrog’s combination of exclusive data, validated technology, and efficient execution makes these partnerships particularly attractive and allows for multiple “shots on goal” with significant upside.
Validation of the platform continues to strengthen. BullFrog’s collaboration with Eleison Pharmaceuticals led to an abstract acceptance at the 2026 ASCO GI Symposium—one of oncology’s most respected venues—highlighting the ability of bfLEAP® and bfPREP™ to identify patient subgroups that may benefit from treatment. When the data are released around January 2026, this could become a major commercial catalyst and further elevate the Company’s visibility among global pharma partners.
With cutting-edge technology, exclusive data access, a capital-efficient operating model, expanding commercial reach, and multiple high-value partnerships on the horizon, BullFrog AI is exceptionally well positioned to create meaningful, scalable value as the biopharma industry accelerates its shift toward AI-powered drug development.
Major Deals Done in AI-Powered Drug Discovery
Investor Presentation
Investment Highlights
Lean Operating Model Creates Outsized Financial Leverage
- Minimal $6.2 million annual burn
- Platform-based model creates multiple “shots on goal,” with each new partner engagement offering meaningful revenue potential and incremental margin impact
- Highly efficient structure enables rapid scalability as clients adopt additional BullFrog AI modules across discovery and development workflows
Sygnature Discovery Collaboration: Accelerating Commercial Adoption
- Global CRO’s team selling BullFrog Data Networks global client network
- Expected to generate up to $15–$30 million in revenue through 2028, establishing a strong commercial baseline
Active Pharma Partnership Discussions with Multi-Deal Potential
- Discussions underway with global biopharma companies across neuropsychiatry and oncology
- Combination of exclusive data, validated AI platforms, and efficient execution makes BullFrog a high-value collaborator
- Each partner engagement offers potential for significant revenues, including upfront and milestones payments, as well as long-term revenue sharing
AI Technology Purpose-Built for Drug Discovery & Development
- bfLEAP® platform, originally developed at Johns Hopkins Applied Physics Lab, delivers causal, multimodal AI insights unmatched by traditional analytics
- Proven ability to identify patient subgroups, drug-response patterns, and novel disease biology across oncology and neuroscience
- Enterprise-ready architecture enables deployment across AWS, Azure, and GCP for global scalability with major pharma partners
Exclusive Access to one of the World’s Largest Brain Data Repository
- Partnership with the Lieber Institute for Brain Development provides access to unparalleled neuropsychiatric data
- Multiple novel drug targets already identified across mental health disorders—an area characterized by long-duration treatment regimens and attractive revenue-sharing potential
- Creates strategic moat and drives partner interest among large pharma companies
Highly Credible External Validation Including ASCO GI Acceptance
- Co-authored abstract with Eleison Pharmaceuticals accepted at the 2026 ASCO GI Symposium—one of oncology’s most respected conferences
- Data release around January 2026 could be a major commercial catalyst as the industry sees real-world impact of bfLEAP® and bfPREP™
Experienced Leadership in AI, Biotech, and Commercial Strategy
- Founder-led team with track record in AI platforms, life sciences, and public markets
Sign Up For BFRG Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Bullfrog AI (BFRG) has been a client of RedChip Companies, Inc. since June 2022. BFRG agreed to pay RedChip an $8,500 monthly cash fee and $50,000 of Rule 144 stock (based on IPO price) for investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. BFRG also agreed to pay RedChip a one-time $20,000 fee for a national TV ad campaign aired February 5 to February 15, 2024, a one-time $20,000 fee for a national TV ad campaign aired July 23 to August 6, 2024, a one-time $40,000 fee for a national TV ad campaign aired April 10 to April 23, 2025, and a one-time $15,000 fee for a national TV ad campaign aired October 15 to October 28, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.